Loading Events

Test Webinar

Test Webinar


In patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) kidney size is a strong predictor of disease progression before eGFR begins to decline1.  Identifying a total kidney volume (TKV) greater than expected for your patient’s age can provide an early and reliable marker for rapid disease progression which is an important step in management to delay further kidney damage1,2.

Did You Know?

  • A one-time kidney size measurement can assess the rate of progression of ADPKD and predict the future decline of kidney function3.
Why Attend This Webinar?
  • For the first time on NephU we are bringing together a Nephrologist and Radiologist to discuss breaking down barriers encountered with TKV orders.
What You Will Learn
  • Review the strengths and limitations of different imaging modalities Nephrologists can order to obtain a TKV.
  • Review different methods Radiologists have available to calculate TKV.
  • Discuss methods to break down communication barriers between the Nephrologist and Radiologist.
  1. Grantham J, et al. (2011). Nat Rev Nephrol. 7(10):556-566.
  2. Chapman A, et al. (2012). Clin J Am Soc Nephrol. 7(3):479-486.
  3. Yu A, et al. (2019). Kidney Int. 95(5):1253-1261.


Neera Dahl

Neera Dahl, MD, PhD

Professor of Medicine (Nephrology), Medical Director of Nephrology and Director of the Nephrology Clinical Trials Program

Yale School of Medicine*

Neera Dahl, MD, PhD is currently a clinician-educator and a Professor of Medicine at Yale University, School of Medicine, Section of Nephrology. She received her MD and PhD from Tufts University School of Medicine and completed her residency and fellowship at the Beth Israel Deaconess Medical Center, in Boston, MA. She has been instrumental in developing the Yale Inherited Kidney Disease Clinical Program and is the principal investigator for several ongoing clinical trials in ADPKD. She maintains an active ADPKD registry and is involved in research exploring the role of inflammation and fibrosis in the progression of ADPKD. She is also the director of the Yale Nephrology Clinical Trials Program and a member of the Scientific Advisory Board for the Polycystic Kidney Disease Foundation.

Jill A. Green

Jill A. Green, PhD

Nephrology Medical Science Director

Otsuka Pharmaceutical Development & Commercialization, Inc.*

Jill A Green, PhD, is a Medical Science Director in the nephrology division at Otsuka Pharmaceutical Development & Commercialization, Inc. Dr Green received her PhD in biomedical sciences, with a specialization in biochemical and molecular basis of disease. She went on to hold a research scientist role at The James Comprehensive Cancer Center at The Ohio State University, specializing in oncology pre-clinical research before taking a position as a Regulatory Compliance Officer where she managed thoracic oncology clinical trials at The James Cancer Hospital.
Dr Green has been a proud member of the PKD Foundation – Columbus, Ohio chapter for over 12 years where she has been active in fundraising and advocacy efforts.

*Dr Dahl is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Dr Green is an employee of OPDC.

If you would like to register for the 1:30 pm to 2:30 pm EDT broadcast, please click below:


Related Resources

Join Today for Instant Access to all NephU Offerings.

Membership is free!

Join NephU today at no cost to register for this event and access to other premium content.

  • The NephU Community is collaborating to improve care and the future outcomes for individuals with kidney disease and other related conditions.
  • Quickly learn more about the topics that interest you.
  • Access our library of on-demand kidney health resources
  • Gain key insights from industry experts & though leaders.